SA
GILD icon

Strategic Advocates’s Gilead Sciences GILD Stock Holding History

Strategic Advocates’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.8K Buy
93
+61
+191% +$8.04K 0.05% 152
2026
Q1 		$4.46K Sell
32
-118
-79% -$16.5K 0.02% 189
2025
Q4 		$18.4K Buy
150
+44
+42% +$5.35K ﹤0.01% 299
2025
Q3 		$11.8K Buy
+106
New +$12K ﹤0.01% 340

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Strategic Advocates's GILD Position: Q2 2026 in Review

Strategic Advocates increased its Gilead Sciences (GILD) stake by 191% in Q2 2026, buying an estimated $8.04K and bringing the position to 93 shares worth $11.8K. The position accounts for 0.05% of the portfolio, ranked #152.

Strategic Advocates first reported a position in GILD in Q3 2025 and has held it in 4 quarters since. The position peaked at $18.4K in Q4 2025. 2,281 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Strategic Advocates held 93 shares of Gilead Sciences worth $11.8K as of Q2 2026.
  • Strategic Advocates bought 61 Gilead Sciences shares in Q2 2026, an estimated $8.04K.
  • Gilead Sciences made up 0.05% of Strategic Advocates's portfolio in Q2 2026, its #152 holding.
  • Strategic Advocates first reported a position in Gilead Sciences in Q3 2025 and has held it in 4 quarters since.
  • Strategic Advocates's Gilead Sciences position peaked at $18.4K in Q4 2025.
  • 2,281 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Strategic Advocates's 13F filing for Q2 2026, filed 13 Aug 2026.